ABVC Biopharma Collaboration Between ABVC And Oncox Biopharma, ABVC Expecting Aggregate Income Of $13.75M And Royalties Of Up To $12.50M; Grants Oncox Exclusive Rights For One Of Abvc's Four Products In Its Oncology Pipeline To Develop, Manufacture, Commercialize Blex 404
Portfolio Pulse from Benzinga Newsdesk
ABVC Biopharma has entered into a collaboration with Oncox Biopharma, granting Oncox exclusive rights to develop, manufacture, and commercialize one of ABVC's four oncology pipeline products, Blex 404. ABVC expects to receive an aggregate income of $13.75 million and up to $12.50 million in royalties from this deal.
May 09, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ABVC Biopharma's collaboration with Oncox Biopharma for Blex 404 could significantly boost its financials with $13.75M expected income and up to $12.5M in royalties.
The collaboration with Oncox Biopharma is directly related to ABVC Biopharma's financial and operational outlook. The expected aggregate income and royalties represent significant revenue streams, likely to positively impact ABVC's stock price in the short term due to the anticipated increase in financial resources and the strategic partnership's potential to accelerate Blex 404's development and commercialization.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100